Hsp22 (HSPB8) Human shRNA Plasmid Kit (Locus ID 26353)

CAT#: TF320676

HSPB8 - Human, 4 unique 29mer shRNA constructs in retroviral RFP vector

Specifications

Product Data

• Locus ID: 26353
• Synonyms: CMT2L; DHMN2; E2IG1; H11; HMN2; HMN2A; HSP22
• Vector: pRFP-C-RS
• Format: Retroviral plasmids
• Kit Components: HSPB8 - Human, 4 unique 29mer shRNA constructs in retroviral RFP vector(Gene ID = 26353). 5µg purified plasmid DNA per construct
  Non-effective 29-mer scrambled shRNA cassette in pRFP-C-RS Vector, TR30015, included for free.
• RefSeq: NM_014365, BC002673
• Summary: The protein encoded by this gene belongs to the superfamily of small heat-shock proteins containing a conservative alpha-crystallin domain at the C-terminal part of the molecule. The expression of this gene in induced by estrogen in estrogen receptor-positive breast cancer cells, and this protein also functions as a chaperone in association with Bag3, a stimulator of macroautophagy. Thus, this gene appears to be involved in regulation of cell proliferation, apoptosis, and carcinogenesis, and mutations in this gene have been associated with different neuromuscular diseases, including Charcot-Marie-Tooth disease. [provided by RefSeq, Jul 2008]
• shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, align it with our published shRNA design sequences. If these do not align, please utilize our custom shRNA service
• Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
  
  For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).